Search research articles
Contact Us
Filters
Showing results (11-20 of 35) with videos related to
Page
of 4
Sort By:
Blood Cancer Journal
|
February 10, 2021
Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report
David L Murray, Noemi Puig, Sigurdur Kristinsson, et al.
Leukemia & Lymphoma
|
December 16, 2025
Daratumumab bortezomib and dexamethasone in transplant ineligible newly diagnosed elderly myeloma patients (AMN006)-a trial by Asian Myeloma Network (NCT03695744)
Melinda S Y Tan, Chandramouli Nagarajan, Melissa Ooi, et al.
Leukemia & Lymphoma
|
February 3, 2018
Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop
Daryl Tan, Jae Hoon Lee, Wenming Chen, et al.
Leukemia & Lymphoma
|
May 10, 2018
Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma
Shaji Kumar, Brian Durie, Hareth Nahi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 18, 2020
Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma
Sikander Ailawadhi, Rachael Sexton, Suzanne Lentzsch, et al.
The Lancet. Haematology
|
December 28, 2020
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial
Saad Z Usmani, Antje Hoering, Sikander Ailawadhi, et al.
Blood Cancer Journal
|
June 17, 2025
A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM)
Chandramouli Nagarajan, Wei-Ying Jen, Melissa Ooi, et al.
Blood Cancer Journal
|
December 10, 2023
Immunophenotypic assessment of clonal plasma cells and B-cells in bone marrow and blood in the diagnostic classification of early stage monoclonal gammopathies: an iSTOPMM study
Oihane Pérez-Escurza, Juan Flores-Montero, Jón Þórir Óskarsson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 25, 2006
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321
Bart Barlogie, Robert A Kyle, Kenneth C Anderson, et al.
BMC Medicine
|
September 10, 2008
Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival
Brian Van Ness, Christine Ramos, Majda Haznadar, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 35) with videos related to
Sort By:
Page
of 4
Blood Cancer Journal
|
February 10, 2021
Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report
David L Murray, Noemi Puig, Sigurdur Kristinsson, et al.
Leukemia & Lymphoma
|
December 16, 2025
Daratumumab bortezomib and dexamethasone in transplant ineligible newly diagnosed elderly myeloma patients (AMN006)-a trial by Asian Myeloma Network (NCT03695744)
Melinda S Y Tan, Chandramouli Nagarajan, Melissa Ooi, et al.
Leukemia & Lymphoma
|
February 3, 2018
Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop
Daryl Tan, Jae Hoon Lee, Wenming Chen, et al.
Leukemia & Lymphoma
|
May 10, 2018
Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma
Shaji Kumar, Brian Durie, Hareth Nahi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 18, 2020
Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma
Sikander Ailawadhi, Rachael Sexton, Suzanne Lentzsch, et al.
The Lancet. Haematology
|
December 28, 2020
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial
Saad Z Usmani, Antje Hoering, Sikander Ailawadhi, et al.
Blood Cancer Journal
|
June 17, 2025
A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM)
Chandramouli Nagarajan, Wei-Ying Jen, Melissa Ooi, et al.
Blood Cancer Journal
|
December 10, 2023
Immunophenotypic assessment of clonal plasma cells and B-cells in bone marrow and blood in the diagnostic classification of early stage monoclonal gammopathies: an iSTOPMM study
Oihane Pérez-Escurza, Juan Flores-Montero, Jón Þórir Óskarsson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 25, 2006
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321
Bart Barlogie, Robert A Kyle, Kenneth C Anderson, et al.
BMC Medicine
|
September 10, 2008
Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival
Brian Van Ness, Christine Ramos, Majda Haznadar, et al.
Page
of 4